Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.
Young, M.A., Shah, N.P., Chao, L.H., Seeliger, M., Milanov, Z.V., Biggs, W.H., Treiber, D.K., Patel, H.K., Zarrinkar, P.P., Lockhart, D.J., Sawyers, C.L., Kuriyan, J.(2006) Cancer Res 66: 1007-1014
- PubMed: 16424036 
- DOI: 10.1158/0008-5472.CAN-05-2788
- Primary Citation of Related Structures:  
2F4J - PubMed Abstract: 
We present a high-resolution (2.0 A) crystal structure of the catalytic domain of a mutant form of the Abl tyrosine kinase (H396P; Abl-1a numbering) that is resistant to the Abl inhibitor imatinib. The structure is determined in complex with the small-molecule inhibitor VX-680 (Vertex Pharmaceuticals, Cambridge, MA), which blocks the activity of various imatinib-resistant mutant forms of Abl, including one (T315I) that is resistant to both imatinib and BMS-354825 (dasatinib), a dual Src/Abl inhibitor that seems to be clinically effective against all other imatinib-resistant forms of BCR-Abl ...